DDInter973 DDInter1376
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Irinotecan {u} (Compound) treats {v} (Disease) hematologic cancer
Irinotecan {u} (Compound) binds {v} (Gene) ABCC1
Irinotecan {u} (Compound) upregulates {v} (Gene) PHLDA3
Irinotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Irinotecan {u} (Compound) downregulates {v} (Gene) PCMT1
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Irinotecan (Compound) treats hematologic cancer (Disease)
Irinotecan (Compound) binds ABCC1 (Gene)
Irinotecan (Compound) upregulates PHLDA3 (Gene)
Irinotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Irinotecan (Compound) downregulates PCMT1 (Gene)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Verapamil